LivaNova (NASDAQ:LIVN) Price Target Increased to $66.00 by Analysts at Robert W. Baird

LivaNova (NASDAQ:LIVN) had its target price boosted by Robert W. Baird from $58.00 to $66.00 in a research report released on Thursday morning, Benzinga reports. They currently have a neutral rating on the stock.

Several other analysts have also recently weighed in on LIVN. StockNews.com raised LivaNova from a hold rating to a buy rating in a report on Thursday, April 25th. Needham & Company LLC reissued a buy rating and issued a $72.00 target price on shares of LivaNova in a research report on Wednesday, May 1st. Barclays raised their price target on shares of LivaNova from $57.00 to $61.00 and gave the stock an equal weight rating in a research report on Monday, February 26th. Finally, Mizuho increased their target price on shares of LivaNova from $75.00 to $80.00 and gave the stock a buy rating in a research report on Thursday. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, LivaNova has a consensus rating of Moderate Buy and a consensus price target of $66.20.

LivaNova Price Performance

Shares of LIVN opened at $64.15 on Thursday. The company’s 50-day moving average is $54.71 and its 200-day moving average is $51.06. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.17 and a quick ratio of 2.51. The firm has a market capitalization of $3.47 billion, a PE ratio of -106.92 and a beta of 0.92. LivaNova has a fifty-two week low of $42.75 and a fifty-two week high of $64.36.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.28. The firm had revenue of $294.90 million for the quarter, compared to analysts’ expectations of $278.17 million. LivaNova had a negative net margin of 2.68% and a positive return on equity of 13.59%. The business’s revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.43 EPS. Equities analysts forecast that LivaNova will post 3.01 EPS for the current year.

Hedge Funds Weigh In On LivaNova

Hedge funds and other institutional investors have recently made changes to their positions in the company. New York State Teachers Retirement System boosted its position in shares of LivaNova by 0.3% during the 1st quarter. New York State Teachers Retirement System now owns 64,322 shares of the company’s stock worth $3,598,000 after acquiring an additional 200 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of LivaNova by 1.8% in the 3rd quarter. Arizona State Retirement System now owns 15,309 shares of the company’s stock valued at $810,000 after purchasing an additional 264 shares in the last quarter. State of Michigan Retirement System increased its stake in shares of LivaNova by 2.3% in the 1st quarter. State of Michigan Retirement System now owns 13,211 shares of the company’s stock valued at $739,000 after purchasing an additional 300 shares during the last quarter. Louisiana State Employees Retirement System raised its holdings in shares of LivaNova by 2.6% during the 1st quarter. Louisiana State Employees Retirement System now owns 15,500 shares of the company’s stock worth $867,000 after buying an additional 400 shares in the last quarter. Finally, Headlands Technologies LLC lifted its position in shares of LivaNova by 33.3% during the 4th quarter. Headlands Technologies LLC now owns 1,807 shares of the company’s stock worth $93,000 after buying an additional 451 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.